CANCER AND LEUKEMIA GROUP B

描述(改编自申请人的摘要)：本申请 代表CALGB机构赠款的第二次竞争性续期 北卡罗来纳大学教堂山分校(UNC-CH)提交的材料和 它的附属公司。UNC-CH自1986年以来一直是CALGB的成员。我们有 在1992-1996年间，平均每年累积120宗案件，并与 增加了七个新的附属机构，包括阿拉巴马大学 伯明翰在过去的三年里，预计将有超过150人在 未来几年。我们总应计收入的大约60%来自我们的 联营公司。我们对少数族裔的整体应计利润率保持在2/2 乘以组平均值。这导致了我们获得了少数人 该集团1997年的计划拨款和北卡罗来纳大学的申请 在即将到来的赠款期间继续资助少数群体倡议计划 周而复始。我们的多学科努力和重大贡献 该组织的外科研究也使我们成为12个组织之一 由大卫博士资助的外科手术补助金的机构 Sugarbaker是首席调查员。此外，我们的机构已经 在团队中表现出广泛的领导力参与辐射 肿瘤学、白血病、淋巴瘤、乳房、移植、相关科学 流行病学、病理学、癌症预防和控制、胃肠道癌症和IS 我们附属医学院的少数民族CCOP研究基地 弗吉尼亚州。在过去的筹资周期中，我们有以下区别 有两个委员会主任，四个委员会副主席，一个工作组 主席，28名核心和执行委员会成员，12名礼宾负责人 调查人员或联合调查人员和两名董事会成员。 这使北卡罗来纳大学始终跻身于 CALGB集团内部评分系统中的“领导力”类别。我们 计划通过保持活跃状态继续为集团提供直接服务 分子流行病学参考实验室和独立资助的 用于患者遗传学研究的种系DNA银行的核心设施 患有乳腺癌和其他实体肿瘤。虽然刘爱迪生博士的 离开NCI对北卡罗来纳大学和整个团队来说都是一个损失，林恩女士 德累斯勒在以下领域拥有丰富的相关研究经验 合作小组将能够继续开展以下工作 这是她和刘博士发起的。我们认为，这份申请反映了 北卡罗来纳大学-CHS调查人员为 领导力、科学和服务方面的团队以及我们对 通过增加主要附属公司来增加应计利润，同时保持 严格的数据提交质量控制。我们恭敬地提出 这份申请既证明了该机构对 集团和UNC-CH及其附属公司将在 未来。

DESCRIPTION (adapted from the applicant's abstract): This application represents the second competitive renewal of the CALGB institutional grant submission from the University of North Carolina at Chapel Hill (UNC-CH) and its affiliates. UNC-CH has been a member of CALGB since 1986. We have maintained an average annual accrual of 120 cases from 1992-1996 and with the addition of seven new affiliates, including the University of Alabama at Birmingham in the last three years, are projecting more than 150 in the coming years. Approximately 60 percent of our total accrual is from our affiliates. Our overall minority accrual of percent remains at two one-half times the group average. This has resulted in our obtaining a Minority Initiative Program Grant from the group for 1997 and an application from UNC for continued Minority Initiative Program funding during the coming Grant cycle. Our multidisciplinary efforts and significant contributions to surgical studies in the group has also resulted in our being one of 12 Group Institutions with funding from the Surgery Grant on which Dr. David Sugarbaker is the Principal Investigator. Moreover, our institution has demonstrated broad leadership participation in the group in Radiation Oncology, Leukemia, Lymphoma, Breast, Transplant, Correlative Sciences, Epidemiology, Pathology, Cancer Prevention and Control, and GI Cancer and is the research base for a Minority CCOP at our affiliate, the Medical College of Virginia. During the past funding cycle, we have had the distinction of having two committee chairs, four committee vice-chairs, one working group chair, 28 Core and Executive Committee members, 12 protocol principal investigators or co-investigators and two members of the Board of Directors. This has ranked UNC consistently among the top two or three institutions in the "leadership" category of the internal CALGB Group scoring system. We plan to continue direct service to the group by maintaining an active reference laboratory in molecular epidemiology and an independently funded core facility for banking of germ line DNA for genetic studies in patients with breast cancer and other solid tumors. Although Dr. Edison Liu's departure to the NCI is a loss for UNC and the entire group, Ms. Lynn Dressler has extensive experience in performing correlative studies within the Cooperative Groups and will be more than able to continue the work which she and Dr. Liu had initiated. We believe that this application reflects the growing and crucial contribution that UNC-CH investigators provide to the group in leadership, science, and service as well as our commitment to increase accrual through the addition of major affiliates while maintaining rigorous quality control of data submission. We respectfully submit that this application demonstrates both the value of this institution to the group and the contributions that UNC-CH and its affiliates will provide in the future.